论文部分内容阅读
目的研究鲍曼不动杆菌对头孢哌酮/舒巴坦及多种抗生素的耐药现状,以及是否可以继续将头孢哌酮/舒巴坦作为临床针对鲍曼不动杆菌的首选经验用药,为防控医院感染提供依据。方法对2011年1月-2015年12月分离的1 558株鲍曼不动杆菌的标本进行了实验室分析;统计了鲍曼不动杆菌对头孢哌酮/舒巴坦等常用抗菌药物的耐药率。结果鲍曼不动杆菌在痰标本的检出率最高为79.6%;对常用抗生素的耐药率基本都在60%以上,而头孢哌酮/舒巴坦2011年耐药率为11.3%,2012年为12.4%,2013年为15.4%,2014年为18.4%,2015年为20.1%。结论鲍曼不动杆菌在临床上主要是由痰液标本中分离得到,常规经验用药头孢哌酮/舒巴坦近5年的耐药性也只呈现轻微的上升趋势,因此可以继续将头孢哌酮/舒巴坦作为临床的首选经验用药,但还需警惕并高度重视该菌感染及耐药监测,以减少耐药菌株的产生和播散。
Objective To study the current status of Acinetobacter baumannii cefoperazone / sulbactam and multiple antibiotics, and whether cefoperazone / sulbactam can continue to be the first choice of clinical practice for Acinetobacter baumannii Prevention and control of nosocomial infections provide the basis. Methods The laboratory analysis of 1 558 strains of Acinetobacter baumannii isolated from January 2011 to December 2015 was carried out. The effects of Acinetobacter baumannii on the common antibacterials such as cefoperazone / sulbactam Drug rates. Results The highest detection rate of Acinetobacter baumannii in sputum specimens was 79.6%. The resistance rate to common antibiotics was above 60%, while that of cefoperazone / sulbactam in 2011 was 11.3%. It was 12.4% annually, 15.4% in 2013, 18.4% in 2014 and 20.1% in 2015. Conclusions Acinetobacter baumannii is mainly isolated from sputum samples in clinical practice. The resistance of cefoperazone / sulbactam to conventional experience has shown only a slight upward trend in the past 5 years. Therefore, cefoperazone Ketone / sulbactam as the clinical experience of choice for the first time, but also need to be vigilant and attach great importance to bacterial infection and drug resistance monitoring to reduce the generation and spread of drug-resistant strains.